Skip to content
lifestyle.humane.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Sight Sciences, Inc.
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
August 19, 2026
Sight Sciences Reports Second Quarter 2026 Financial Results
August 5, 2026
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems
August 5, 2026
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
August 4, 2026
Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
July 22, 2026
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
May 24, 2026
Sight Sciences to Present at Two Upcoming Investor Conferences
May 22, 2026
Sight Sciences Announces the Release of its Sustainability Report
May 21, 2026
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
April 21, 2026
Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 1, 2026
1
2
Next Page
→